These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 11160021)

  • 21. The humoral immune responses elicited in mice by inoculations with a recombinant protein or DNA based on the circumsporozoite-protein gene of Plasmodium falciparum.
    Fang Z; Liu YW; Shi YK; Yu XB; Huang WQ; Ji X
    Ann Trop Med Parasitol; 2002 Jul; 96(5):463-8. PubMed ID: 12194706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
    Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
    J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pre-erythrocytic malaria vaccines to prevent Plasmodium falciparum malaria.
    Ballou WR; Kester KE; Heppner DG
    Chem Immunol; 2002; 80():253-61. PubMed ID: 12058643
    [No Abstract]   [Full Text] [Related]  

  • 26. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A.
    Brando C; Ware LA; Freyberger H; Kathcart A; Barbosa A; Cayphas S; Demoitie MA; Mettens P; Heppner DG; Lanar DE
    Infect Immun; 2007 Feb; 75(2):838-45. PubMed ID: 17101665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
    Bergmann ES; Ballou RW; Krzych U
    Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of murine cytotoxic T lymphocytes against Plasmodium falciparum sporozoite surface protein 2.
    Wizel B; Rogers WO; Houghten RA; Lanar DE; Tine JA; Hoffman SL
    Eur J Immunol; 1994 Jul; 24(7):1487-95. PubMed ID: 7517870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein.
    Munesinghe DY; Clavijo P; Calle MC; Nussenzweig RS; Nardin E
    Eur J Immunol; 1991 Dec; 21(12):3015-20. PubMed ID: 1721025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
    BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
    Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses.
    Sedegah M; Rogers WO; Belmonte M; Belmonte A; Banania G; Patterson NB; Rusalov D; Ferrari M; Richie TL; Doolan DL
    Vaccine; 2010 Apr; 28(17):3055-65. PubMed ID: 19879998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Humoral immune response in mice to hybrid nucleic acid vaccines containing Plasmodium falciparum merozoite surface protein 1 block 17-based gene].
    Miao J; Li X; Xue C; Zhen R; Liu Z; Qin E; Yu Q
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1999; 17(5):302-4. PubMed ID: 12563865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen.
    Jones TR; Narum DL; Gozalo AS; Aguiar J; Fuhrmann SR; Liang H; Haynes JD; Moch JK; Lucas C; Luu T; Magill AJ; Hoffman SL; Sim BK
    J Infect Dis; 2001 Jan; 183(2):303-312. PubMed ID: 11110648
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potent induction of focused Th1-type cellular and humoral immune responses by RTS,S/SBAS2, a recombinant Plasmodium falciparum malaria vaccine.
    Lalvani A; Moris P; Voss G; Pathan AA; Kester KE; Brookes R; Lee E; Koutsoukos M; Plebanski M; Delchambre M; Flanagan KL; Carton C; Slaoui M; Van Hoecke C; Ballou WR; Hill AV; Cohen J
    J Infect Dis; 1999 Nov; 180(5):1656-64. PubMed ID: 10515829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How elusive can a malaria vaccine be?
    Pance A
    Nat Rev Microbiol; 2019 Mar; 17(3):129. PubMed ID: 30626910
    [No Abstract]   [Full Text] [Related]  

  • 37. Reduced immunogenicity of DNA vaccine plasmids in mixtures.
    Sedegah M; Charoenvit Y; Minh L; Belmonte M; Majam VF; Abot S; Ganeshan H; Kumar S; Bacon DJ; Stowers A; Narum DL; Carucci DJ; Rogers WO
    Gene Ther; 2004 Mar; 11(5):448-56. PubMed ID: 14973538
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The naturally acquired immunity in severe malaria and its implication for a PfEMP-1 based vaccine.
    Chen Q
    Microbes Infect; 2007 May; 9(6):777-83. PubMed ID: 17398133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New candidate vaccine neutralizes all tested strains of malaria parasite.
    Hum Vaccin Immunother; 2012 Feb; 8(2):153-4. PubMed ID: 22745944
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.